RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy

Oncogene. 2020 Oct;39(43):6704-6718. doi: 10.1038/s41388-020-01447-0. Epub 2020 Sep 21.

Abstract

Autophagy can protect stressed cancer cell by degradation of damaged proteins and organelles. However, the regulatory mechanisms behind this cellular process remain incompletely understood. Here, we demonstrate that RSK2 (p90 ribosomal S6 kinase 2) plays a critical role in ER stress-induced autophagy in breast cancer cells. We demonstrated that the promotive effect of RSK2 on autophagy resulted from directly binding of AMPKα2 in nucleus and phosphorylating it at Thr172 residue. IRE1α, an ER membrane-associated protein mediating unfolded protein response (UPR), is required for transducing the signal for activation of ERK1/2-RSK2 under ER stress. Suppression of autophagy by knockdown of RSK2 enhanced the sensitivity of breast cancer cells to ER stress both in vitro and in vivo. Furthermore, we demonstrated that inhibition of RSK2-mediated autophagy rendered breast cancer cells more sensitive to paclitaxel, a chemotherapeutic agent that induces ER stress-mediated cell death. This study identifies RSK2 as a novel controller of autophagy in tumor cells and suggests that targeting RSK2 can be exploited as an approach to reinforce the efficacy of ER stress-inducing agents against cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects
  • Autophagy*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology*
  • Cell Nucleus / metabolism
  • Drug Resistance, Neoplasm
  • Endoplasmic Reticulum Stress / drug effects
  • Endoribonucleases / metabolism
  • Female
  • Gene Knockdown Techniques
  • Humans
  • MAP Kinase Signaling System / drug effects
  • MCF-7 Cells
  • Mice
  • Paclitaxel / pharmacology
  • Paclitaxel / therapeutic use
  • Phosphorylation
  • Protein Serine-Threonine Kinases / metabolism
  • Ribosomal Protein S6 Kinases, 90-kDa / genetics
  • Ribosomal Protein S6 Kinases, 90-kDa / metabolism*
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • ERN1 protein, human
  • PRKAA2 protein, human
  • Protein Serine-Threonine Kinases
  • Ribosomal Protein S6 Kinases, 90-kDa
  • ribosomal protein S6 kinase, 90kDa, polypeptide 3
  • AMP-Activated Protein Kinases
  • Endoribonucleases
  • Paclitaxel